Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a
patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or
bevacizumab, and allow doctors to plan better treatment.
PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic
treatment in patients with advanced kidney cancer.